We excluded clinical variables and developed a gene-only version of the BCT Gene Score to evaluate its independent prognostic performance.<h4>Methods</h4>We assessed the prognostic value of the BCT Gene Score in a cohort of patients with ER+/HER2- early breast cancer using available Oncotype DX Recurrence Score (RS) data. The gene discussed is ERBB2; the disease is breast carcinoma.